Blueprint
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending 18 July 2016
 
GlaxoSmithKline plc
(Name of registrant)

 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
 
Yes      No x
--
 
 
GlaxoSmithKline plc (the 'Company')
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description
of
the
financial
 
instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
  
 
b)
Nature
of
the
transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 July 2016, on shares held through the Company's ShareReward Plan.  
 
c)
Price(s)
and
volume(s)
  Price(s)
 Volume(s)
  £16.6373
  54
d)
Aggregated
information
 
Aggregated
volume
Price
n/a (single transaction)
 
 
 
 
 
 
e)
Date of
the
transaction
2016-07-14
f)
Place
of
the transaction
 
London Stock Exchange (XLON)
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
 
 
GlaxoSmithKline plc
(Registrant)

Date: July 18, 2016 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc